[go: up one dir, main page]

MXPA03010742A - Preparacion farmaceutica que presenta excelente estabilidad en almacenamiento. - Google Patents

Preparacion farmaceutica que presenta excelente estabilidad en almacenamiento.

Info

Publication number
MXPA03010742A
MXPA03010742A MXPA03010742A MXPA03010742A MXPA03010742A MX PA03010742 A MXPA03010742 A MX PA03010742A MX PA03010742 A MXPA03010742 A MX PA03010742A MX PA03010742 A MXPA03010742 A MX PA03010742A MX PA03010742 A MXPA03010742 A MX PA03010742A
Authority
MX
Mexico
Prior art keywords
medicinal composition
pharmacologically active
active substance
dispersing
dissolving
Prior art date
Application number
MXPA03010742A
Other languages
English (en)
Inventor
Yomohira Yuso
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of MXPA03010742A publication Critical patent/MXPA03010742A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Una composicion medicinal que tiene excelente estabilidad en almacenamiento y, aun durante almacenamiento prolongado, es menos propensa a cambiar en la velocidad de liberacion de la sustancia farmacologicamente activa contenida en la misma; la composicion medicinal se obtiene al disolver o dispersar una sustancia farmacologicamente activa y un polimero insoluble en agua independiente del pH en una sustancia con bajo punto de fusion fundida; se produce al disolver o dispersar la sustancia farmacologicamente activa en una mezcla fundida de la sustancia con bajo punto de fusion y el polimero insoluble en agua independiente del pH y asperjando y enfriando el liquido resultante.
MXPA03010742A 2001-05-25 2002-05-23 Preparacion farmaceutica que presenta excelente estabilidad en almacenamiento. MXPA03010742A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2001156815 2001-05-25
JP2001319075A JP4310605B2 (ja) 2001-05-25 2001-10-17 医薬用組成物
PCT/JP2002/004979 WO2002096466A1 (fr) 2001-05-25 2002-05-23 Composition de medicament

Publications (1)

Publication Number Publication Date
MXPA03010742A true MXPA03010742A (es) 2004-03-02

Family

ID=26615705

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03010742A MXPA03010742A (es) 2001-05-25 2002-05-23 Preparacion farmaceutica que presenta excelente estabilidad en almacenamiento.

Country Status (10)

Country Link
US (1) US8703189B2 (es)
EP (1) EP1398040A4 (es)
JP (1) JP4310605B2 (es)
KR (1) KR100943347B1 (es)
CN (1) CN100404071C (es)
AU (1) AU2002258221B2 (es)
CA (1) CA2445388C (es)
MX (1) MXPA03010742A (es)
TW (1) TWI293883B (es)
WO (1) WO2002096466A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005000312A1 (ja) 2003-06-27 2005-01-06 Otsuka Pharmaceutical Co., Ltd. 薬物徐放性粒子及びその製法
NZ555693A (en) 2004-12-27 2010-10-29 Eisai R&D Man Co Ltd Matrix type sustained-release preparation containing donepezil
TWI320783B (en) 2005-04-14 2010-02-21 Otsuka Pharma Co Ltd Heterocyclic compound
EP1945047A1 (en) * 2005-11-08 2008-07-23 Accelis Fomulations Ltd. Diet supplement and method for weight-loss
EP1970040A4 (en) * 2005-12-22 2013-05-29 Otsuka Pharma Co Ltd METHOD FOR PRODUCING MEDICINAL WAX MATRIX PARTICLES, IN THE METHOD OF USING EXTRUDERS AND CILOSTAZOL-CONTAINING PREPARATION WITH DELAYED RELEASE
ZA200805793B (en) * 2005-12-22 2009-11-25 Otsuka Pharma Co Ltd Method of producing drug-containing wax matrix particles, extruder to be used in the method and sustained-release preparation containing cilostazol
EP1880714A1 (en) 2006-07-20 2008-01-23 Helm AG Amorphous Aripiprazole and Process for the Preparation thereof
US7799790B2 (en) 2006-07-20 2010-09-21 Helm Ag Amorphous aripiprazole and process for the preparation thereof
KR20080076382A (ko) * 2007-02-15 2008-08-20 (주)아모레퍼시픽 실로스타졸의 제어방출 제제 및 그 제조방법
EP2155167A2 (en) 2007-06-04 2010-02-24 Egalet A/S Controlled release pharmaceutical compositions for prolonged effect
PT2082735E (pt) 2008-01-23 2010-10-12 Helm Ag Aripripazole amorfo e processo para a sua preparação
EP2393484A1 (en) 2009-02-06 2011-12-14 Egalet Ltd. Immediate release composition resistant to abuse by intake of alcohol
EP2445487A2 (en) 2009-06-24 2012-05-02 Egalet Ltd. Controlled release formulations
TR201000948A1 (tr) 2010-02-09 2011-08-22 Sanovel İlaç San.Ve Ti̇c.A.Ş. Aripiprazol formülasyonları.
KR101182114B1 (ko) * 2010-03-05 2012-09-12 한림제약(주) 유효성분으로서 레바미피드를 함유하는 골관절염 예방 또는 치료용 약학 조성물
EP2875830A4 (en) 2012-07-20 2016-02-24 Otsuka Pharma Co Ltd TABLET HAVING DRY INK FILM ON THE SURFACE THEREOF, AND INK FOR INKJET PRINTER
JP7636325B2 (ja) * 2018-12-18 2025-02-26 ニュートリション アンド バイオサイエンシズ ユーエスエー １，リミティド ライアビリティ カンパニー エチルセルロースを含む徐放性組成物
US20220218616A1 (en) * 2019-04-15 2022-07-14 Sunsho Pharmaceutical Co., Ltd. Tablet and method for producing tablet
EP4119129A4 (en) * 2020-03-11 2024-01-24 Sawai Pharmaceutical Co., Ltd. GRANULES AND THEIR USE
CN112516105A (zh) * 2020-12-10 2021-03-19 成都恒瑞制药有限公司 一种氯沙坦钾口服制剂及其制备方法
JP2024115533A (ja) * 2023-02-14 2024-08-26 沢井製薬株式会社 コーティング顆粒、コーティング顆粒を含む製剤及びそれらの製造方法
CN118236336B (zh) * 2024-04-07 2024-10-01 山东新时代药业有限公司 一种含西洛他唑的片剂及其制备

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL193682C (nl) * 1987-05-14 2000-07-04 Glaxo Group Ltd Beklede cefuroximaxetilsamenstelling.
NZ231281A (en) 1988-11-08 1991-01-29 Takeda Chemical Industries Ltd Sustained release pharmaceutical preparations comprising the active agent dispersed in a solid matrix of a fatty acid ester of a polyglycerol
JP2893191B2 (ja) * 1988-11-08 1999-05-17 武田薬品工業株式会社 放出制御性マトリックス剤
IL92343A0 (en) * 1988-12-20 1990-07-26 Gist Brocades Nv Granulate for multiparticulate controlled release oral compositions,their preparation and oral pharmaceutical compositions containing them
JP3130058B2 (ja) 1991-02-15 2001-01-31 第一製薬株式会社 マスクされた粒状物
CA2150119C (en) * 1992-11-30 2005-03-15 Robert C. Cuca Tastemasked pharmaceutical materials
US5656291A (en) * 1994-03-16 1997-08-12 Pharmacia & Upjohn Aktiebolag Controlled release preparation
JP3247511B2 (ja) 1993-09-07 2002-01-15 山之内製薬株式会社 医薬用組成物
US5965161A (en) 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
JPH08143450A (ja) 1994-11-14 1996-06-04 Taiyo Yakuhin Kogyo Kk 徐放化製剤
ATE251896T1 (de) * 1994-12-19 2003-11-15 Daiichi Seiyaku Co Granulat-präparate mit kontinuierlicher freisetzung und verfahren zur herstellung
DE19504831A1 (de) * 1995-02-14 1996-09-05 Basf Ag Feste Wirkstoffzubereitungen enthaltend Hydroxypropylcellulose
AU700961B2 (en) 1995-07-21 1999-01-14 Daiichi Pharmaceutical Co., Ltd. Granular preparation and producing process thereof
ES2199289T3 (es) * 1995-07-26 2004-02-16 Kyowa Hakko Kogyo Co., Ltd. Dispersion solida de derivados de xantina.
WO1998042323A1 (en) * 1997-03-25 1998-10-01 Takeda Chemical Industries, Ltd. Stabilized urease inhibitor
ES2263211T3 (es) 1997-07-02 2006-12-01 Euro-Celtique S.A. Formulaciones de tramadol de liberacion sostenida estabilizada.
JP3611456B2 (ja) * 1997-09-30 2005-01-19 日研化学株式会社 テオフィリン徐放性錠剤
US6328993B1 (en) * 1997-12-08 2001-12-11 Byk Gulden Lomberg Chemische Fabrik Gmbh Oral administration form for an acid liable active proton pump inhibitor
JP2000169364A (ja) * 1998-09-30 2000-06-20 Taisho Pharmaceut Co Ltd 経口製剤用粒子
AU5997999A (en) * 1998-09-30 2000-04-17 Taisho Pharmaceutical Co., Ltd. Grains for oral preparations
SI1187601T1 (sl) * 1999-06-07 2005-12-31 Altana Pharma Ag Novi pripravek in dajalna oblika, ki obsega kislinsko labilen inhibitor protonske crpalke

Also Published As

Publication number Publication date
CN100404071C (zh) 2008-07-23
CA2445388A1 (en) 2002-12-05
US20040175422A1 (en) 2004-09-09
WO2002096466A1 (fr) 2002-12-05
TWI293883B (en) 2008-03-01
AU2002258221B2 (en) 2007-08-23
CA2445388C (en) 2010-07-13
EP1398040A1 (en) 2004-03-17
HK1065257A1 (zh) 2005-02-18
US8703189B2 (en) 2014-04-22
CN1509185A (zh) 2004-06-30
KR20040004641A (ko) 2004-01-13
EP1398040A4 (en) 2011-03-02
JP2003040764A (ja) 2003-02-13
JP4310605B2 (ja) 2009-08-12
KR100943347B1 (ko) 2010-02-22

Similar Documents

Publication Publication Date Title
MXPA03010742A (es) Preparacion farmaceutica que presenta excelente estabilidad en almacenamiento.
ATE219932T1 (de) Neue feste dosisform enthaltend nanopartikelnaproxen
MY144992A (en) Substituted 1,2,3,4-tetrahydroisoquinoline derivatives.
BR0003158A (pt) Formulação de dosagem oral de derretimentoinstantâneo
WO2001085212A3 (en) Drug delivery systems for photodynamic therapy
ATE391708T1 (de) Verbindungen und gemische zur verabreichung eines aktiven agens
EA200400045A1 (ru) Система для ингаляции сухим порошком для транспульмонарного применения
MXPA05009194A (es) Estuche generador de espuma que contiene un despachador generador de espuma y una composicion de alta viscosidad.
MY120177A (en) Detergent compositions
WO2001085137A3 (en) Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
NZ520624A (en) 1,2,3,4-tetrahydroisoquinoline derivatives
MXPA02012937A (es) Combinaciones de productos activos con propiedades insecticidas y acaricidas.
WO2003035051A3 (en) The use of proton sequestering agents in drug formulations
MXPA03011440A (es) Composicion de liberacion sostenida y proceso para producirla.
ATE262277T1 (de) Wasser-dispergierbare agrochemische zusammensetzungen
CA2352915A1 (en) Pharmaceutical compositions containing mupirocin
CA2534664A1 (en) Modafinil compositions
CA2446221A1 (en) Stable powder inhalation dosage formulation
WO2002015880A3 (en) Powdered mannitol and mannitol-containing compositions
WO2003074033A8 (en) Sustained/controlled release solid formulation as a novel drug delivery system with reduced risk of dose dumping
MXPA04003506A (es) Metodo para la preparacion de una composicion farmaceutica que comprende acido 5-aminosalicilico para el uso en el tratamiento de la colitis ulcerativa y de la enfermedad de crohn.
WO2002008200A3 (en) Arylethene-sulfonamides, their preparation and their use as endothelin antagonists
ATE341307T1 (de) Quaternäre verbindungen enthaltend propolis als wirkstoff
DE50105710D1 (de) Pharmazeutische, ramipril enthaltende brauseformulierung
ATE412404T1 (de) Stabile orale pharmazeutische zusammensetzungen von buprenorphin und salz davon

Legal Events

Date Code Title Description
FG Grant or registration